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Abstract
Background: Human papillomavirus (HPV) is the most widespread sexually transmitted infection worldwide. It
causes several health consequences, in particular accounting for the majority of cervical cancer cases in women. In
the United Kingdom, a vaccination campaign targeting 12-year-old girls started in 2008; this campaign has been
successful, with high uptake and reduced HPV prevalence observed in vaccinated cohorts. Recently, attention has
focused on vaccinating both sexes, due to HPV-related diseases in males (particularly for high-risk men who have sex
with men) and an equity argument over equalising levels of protection.
Methods: We constructed an epidemiological model for HPV transmission in the UK, accounting for nine of the
most common HPV strains. We complemented this with an economic model to determine the likely health outcomes
(healthcare costs and quality-adjusted life years) for individuals from the epidemiological model. We then tested
vaccination with the three HPV vaccines currently available, vaccinating either girls alone or both sexes. For each
strategy we calculated the threshold price per vaccine dose, i.e. the maximum amount paid for the added health
benefits of vaccination to be worth the cost of each vaccine dose. We calculated results at 3.5% discounting, and also
1.5%, to consider the long-term health effects of HPV infection.
Results: At 3.5% discounting, continuing to vaccinate girls remains highly cost-effective compared to halting
vaccination, with threshold dose prices of £56-£108. Vaccination of girls and boys is less cost-effective (£25-£53).
Compared to vaccinating girls only, adding boys to the programme is not cost-effective, with negative threshold
prices (-£6 to -£3) due to the costs of administration. All threshold prices increase when using 1.5% discounting, and
adding boys becomes cost-effective (£36-£47). These results are contingent on the UK’s high vaccine uptake; for lower
uptake rates, adding boys (at the same uptake rate) becomes more cost effective.
Conclusions: Vaccinating girls is extremely cost-effective compared with no vaccination, vaccinating both sexes is
less so. Adding boys to an already successful girls-only programme has a low cost-effectiveness, as males have high
protection through herd immunity. If future health effects are weighted more heavily, threshold prices increase and
vaccination becomes cost-effective.
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Background
Human papillomavirus (HPV) is the world’s most com-
mon sexually transmitted infection, with the majority
of people being infected at some point in their lifetime
[1, 2]. At any time, up to 44% of sexually active women are
infected [3, 4]. Although for most people it is symptom-
less and they recover from the infection with no adverse
effects, for a small proportion the infection may lead to
adverse health sequelae. Of the 200 strains known and 120
catalogued thus far [5, 6], at least 18 have been labelled
‘high-risk’ HPV types due to their associations with devel-
opment of different cancers [7]; in particular, strains 16
and 18 are associated with the majority of cervical can-
cers [8, 9]. The high health and economic burden caused
by HPV infection has led to many countries initiating
HPV vaccinations campaigns.. Available vaccines include:
a bivalent vaccine protecting against HPV-16 and HPV-
18 (Cervarix®) and a quadrivalent vaccine, which also
protects against HPV-6 and HPV-11 (Gardasil®), both of
which are linked to genital warts in both sexes [10]. A non-
avalent vaccine (Gardasil 9®) has recently been approved
for administration which, in addition to the aforemen-
tioned types, also protects against HPV types 31, 33, 45,
52, and 58. Uptake in different countries has varied con-
siderably since the introduction of HPV vaccination. The
United Kingdom (UK), which is the primary focus of this
work, has relatively high national uptake rates of around
76-90% [11]. Australia and Portugal also have relatively
high uptake rates (70-80%), while some countries such
as the USA, France and New Zealand have low uptake
(21-47%) [12–15]. Some low and middle income countries
such as Rwanda and Bhutan have also successfully set up
programmes with extremely high reported uptake rates of
93-99% [16, 17].
Vaccinating when young, before sexual debut, is optimal
[18, 19]. Early immunisation programmes targeted young
teenage girls, with the focus on reducing incidence of cer-
vical cancer later in life. In 2007, Australia targeted a wider
age range of girls / women aged 12-26 as part of a limited
catch-up programmes [20], and improvements in overall
health outcomes have been shown in boys as well as girls
due to indirect protection [21]. In the UK, teenage girls
(aged 12-13) have been vaccinated in school since 2008,
initially using the bivalent vaccine, replaced by the quadri-
valent since 2011 [22]. National vaccination coverage has
been consistently high since vaccination began, in the
region of 76-90% [11, 23], making the programme one of
the most successful globally in combating HPV. A catch-
up programme for older girls was also implemented for
three years (2008-2011), whereby 13-18 year old girls who
missed out due to their age were also offered the vaccine
[24]. Original models [19, 25] predicted it would be cost-
effective to vaccinate teenage girls, provided the duration
of protection was at least ten years, as it would lower the
incidence of subsequent health conditions arising from
HPV infection, in particular cervical cancer, which is a
major health burden [26]. Recently, the decision was made
to reduce the three-dose schedule (two primers plus one
booster) to two doses (one primer plus one booster), fol-
lowing immunological evidence for comparable efficacy
[27, 28] and improved cost-effectiveness [29].
In 2011 Giuliano et al. [30] questioned whether or not it
would be cost-effective to include additional target groups
to vaccination programmes, given that the HPV vaccine
is efficacious in both sexes. A 2016 meta-analysis by Bris-
son et al. [31] provides an overview of the herd effects of
vaccinating girls. Studies have shown some groups to have
relatively high prevalence of HPV and significant health
effects, including HIV-positive individuals [32, 33], and
men who have sex with men (MSM) [34, 35]; the latter
benefit less from the herd immunity generated by vacci-
nating girls than heterosexual men. Modelling has shown
(as is intuitive) that increasing targets for vaccination,
such as adding boys to a girls-only programme [18], and
including adults [36], leads to further reductions in preva-
lence. However, in terms of cost-effectiveness, results
of health economic analyses of contrasting programmes
have generated less clear cut results. Most studies show
vaccination of girls is highly cost-effective in many coun-
tries despite different cost-effectiveness thresholds for
health improvements (e.g.[19, 37, 38], while the major-
ity of studies that have proposed adding males to a
female-only vaccination programme found it was less
cost-effective compared to vaccinating only females [39,
40] and, in most cases, not cost-effective using standard
thresholds of willingness to pay [24, 41–43]. A US study
found that it would only be cost-effective if coverage in
girls was around 20% [44]. Research in Australia also
showed a limited impact of boys’ vaccination on HPV
infections and related cancers in males [45], although
Australia subsequently became the first country to adopt
national gender-neutral vaccination of boys as well as
girls [46]; New Zealand also added boys to the national
programme in 2016. An analysis of vaccinating MSM in
the USA found that it could be cost-effective, although
it assumed the current vaccination programme in girls
had no effect on HPV prevalence in MSM [47]. There
thus remain many questions as to the cost-effectiveness
of expanding the current girls-only strategy in the UK; we
focus on the specific problem of adding teenage boys to
the current vaccination programme.
Here we present an analysis of HPV infection and vac-
cination, to estimate the incremental cost-effectiveness of
vaccinating boys as well as girls. The study consists of
three parts: firstly, the fitting of parameters associated
with HPV transmission, infection and recovery, by use
of an epidemiological model incorporating sexual part-
nerships between individuals, matched to multiple HPV
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prevalence data sources. Secondly, the simulation of a
range of vaccination strategies using the parameters from
the above model. Thirdly, an economic analysis of the
different strategies, taking into account the potential con-
sequences (including health-related quality of life and
cost implications) of HPV infections, to assess the cost-
effectiveness of each vaccination strategy. We have not
included potential changes to the UK’s cervical cancer
screening service that might be precipitated by any future
reduction in HPV prevalence. In this regard we follow
the earlier analysis of female-only vaccination [19] and
focus on the epidemiological and economic impacts of
vaccination.
Methods
Data
HPV prevalence data pre-vaccination
To fit the transmission model to HPV prevalence rates
before vaccination programmes were introduced, a vari-
ety of data, across a range of countries, was used. In total,
results from 13 detailed epidemiological studies were
used; information is given in Additional file 3: Table S1.
Data consisted of either prevalence of serum antibodies
against HPV types, or HPV DNA presence in the epithe-
lial layer. The sex and age (groups) of individuals in each
study were generally known, as well as, in the case of the
studies by Nielson et al. [48] and Tanton et al. [49], sex-
ual activity of individuals, and in the case of the study by
King et al. [35], sexual orientation. These data were used
to infer the infection parameters of our model including
type-specific transmission probabilities.
Partnership rates
To model partnership behaviour of individuals, we used
data from National Survey of Sexual Attitudes and
Lifestyles (NATSAL) 2 and 3 [50]: UK-wide surveys of
sexual behaviour. We fitted distributions to stratified data
which allowed us to determine the annual rates of forming
new sexual partners where there is unprotected inter-
course, as well as the likely ages of these partners. Indi-
viduals were stratified by age, sex, sexual preference and
previous sexual experience. For all simulations, we used
NATSAL-2 distributions up to 2010, and NATSAL-3 dis-
tributions simulating forwards from 2010.
Epidemiological model
In the following section we describe the epidemiological
model in brief; the transmission framework is explored in
more detail in Datta et al. [50], and in Additional file 1:
Appendix S1.
We used an individual-based modelling framework,
with SIRS-V (Susceptible - Infected - Recovered - Sus-
ceptible - Vaccinated) dynamics, thus accounting for
both short-duration natural immunity and longer-lasting
protection due to vaccination. Populations of 50,000 indi-
viduals were generally modelled; this population size
was a compromise between stochastic uncertainty and
speed of the computationally intensive simulations. We
used yearly data from Natsal-2 and Natsal-3 to deter-
mine distributions for the rates of new partnerships that
involve unprotected sex and could therefore allow the
spread of HPV [50]. Different distributions were defined
depending on four personal characteristics: age (years),
sex (male/female), sexual orientation (heterosexual/any
other) and previous sexual experience (yes/no). Individu-
als in the population were given a risk-percentile, which
determined the values extracted from the distribution of
rates, with the distribution defined by the individual’s
characteristics (e.g. age, sex, etc). This meant that high
risk-percentile individuals consistently had high rates of
new partnerships relative to their peers. However, we
know that individual behaviour patterns can change (e.g.
by starting a long-term relationship); we therefore allowed
risk-percentiles to be randomly redrawn with a low age-
and sex-dependent probability - this allowed us to cap-
ture longer term (5-year and lifetime) behaviour from the
NATSAL surveys.
The model was generally run for 100 years, allow-
ing individuals to age, form new partnerships, become
infected and recover. When an individual stochastically
picked a new partner, the characteristics of the new part-
ner were probabilistically determined by the status of the
individual choosing. If the chosen partner was infected
with one or more types of HPV, these could be stochasti-
cally transferred, with separate transmission probabilities
for each type and with asymmetric transmission between
the sexes [51]. Once infected, an individual had a rate
of recovery, equal for all types, and may have generated
a detectable serological response (separate probabilities
for males and females) allowing us to match the model
to serological data. After recovery, there was a period
of strain-specific natural immunity before the individ-
ual became susceptible once more. In total, the model
required fifteen HPV-specific parameters to be inferred
from the empirical data.
We used 13 datasets to fit the parameters in the epi-
demiological model; the datasets used are listed in Additional
file 3: Table S1. All data were either serological data
(detecting the presence / absence of antibodies which
the individual produced naturally after a previous or cur-
rent infection), or DNA data (indicative of a current HPV
infection). Although serological data were more widely
available, the probability of producing antibodies follow-
ing an infection is not high; probabilities are thought
to be around 60% for females [52] and 30% for males,
although some studies report much lower type-specific
rates[53]. These serological probabilities were inferred as
part of the model-fitting process. DNA data, on the other
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hand, was considered more reliable, and we therefore
assumed 100% sensitivity and specificity of these data. The
model parameters were inferred using a Bayesian Markov
Chain Monte Carlo (MCMC) framework and a standard
Metropolis-Hastings algorithm. Likelihoods were gener-
ated by assuming that the data reflected a binomial sample
of the model population.
Simulating vaccination strategies
For predicting the impact of vaccination, we followed the
UK’s Joint Committee on Vaccination and Immunisation
(JCVI) guidelines and used the ‘best’ parameters from
the model fitting (i.e. the mode from the posterior for
each fitted parameter). We then estimated future levels of
HPV in the population for different vaccination strategies.
Although the parameters used for each run were identi-
cal, due to the stochastic nature of the simulation, there
was considerable variability between runs necessitating
multiple simulations (500 runs per vaccination strategy).
When simulating future vaccination scenarios, we used
available uptake rates to simulate the girls-only vaccina-
tion that had occurred in the period 2008-2016 inclusive,
using the bivalent vaccine until 2012, and quadrivalent
after that [11, 54]; we also took into account the catch-
up campaigns targeting girls aged 13-18 that occurred in
2008-11. (Uptake rates for both the routine and catch-
up campaigns are shown in Additional file 4: Table S2.)
For both campaigns, we conservatively assumed that only
girls who received all three HPV doses were protected.
The three available vaccines, are each assumed to confer
complete protection for their target types (16 and 18 for
the bivalent vaccine; 6, 11, 16 and 18 for the quadrivalent
vaccine; and 6, 11, 16, 18, 31, 33, 45, 52 and 58 for the non-
avalent vaccine) but differing levels of cross-protection
to any remaining modelled HPV types (Additional file 5:
Table S3). Forward simulations generated lifetime his-
tories of individuals, for use in the economic analysis
(see next section). Note that we assumed a two dose
schedule (vaccine plus booster) for all future strategies,
following evidence that this is likely to be more cost-
effective than three doses if vaccine protection is at least
20 years [29]. We assumed for simplicity that both doses
were given simultaneously to individuals, and protection
began immediately. Therefore we did not have to explicitly
model the first dose.
The following vaccination strategies were simulated into
the future, using the bivalent, quadrivalent or nonavalent
vaccine. We define ‘historical vaccination’ as simulating
girls-only vaccination for 2008-2016, with uptake rates
for the main and catch-up programmes taken from UK
data (Additional file 4: Table S2), and the respective new
strategies began at the start of 2017:
1. Halted vaccination: historical vaccination, followed
by a halting of all vaccination in 2017;
2. Girls: historical vaccination, followed in 2017 by
selecting 85% of 12-year-old females to be vaccinated
at the start of each year (based on predictions from
JCVI on future uptake rates);
3. Girls and boys: historical vaccination, followed in
2017 by selecting 85% of 12-year old girls and 85% of
12-year old boys to be vaccinated at the start of each
year (this assumed that boys’ uptake would be equal
to that of girls);
4. Girls and boys equal: historical vaccination, followed
in 2017 by selecting 42.5% of 12-year old girls and
42.5% of 12-year old boys at the start of each year to
be vaccinated (hence an equal level of vaccination as
girls’ vaccination (strategy 2));
5. Girls naïve: no historical vaccination, and vaccinating
60% of 12-year old girls from 2008 onwards;
6. Girls and boys naïve: no historical vaccination, and
vaccinating 60% of 12-year old girls and 60% of
12-year old boys from 2008 onwards.
Halted vaccination was included, not as a plausible future
strategy, but so that the threshold vaccine prices could
be compared to a baseline (analogous to starting a new
vaccination programme compared to not beginning one).
The final three scenarios were designed to provide a
scientific understanding of the generic conditions under
which a gender-neutral vaccination programme would
be cost-effective. Strategy 4 represents countries (like
the UK) that have already commenced a girls-only vac-
cination programme (at varying uptake rates) and are
interested in adding boys to the schedule; whilst strate-
gies 5 and 6 represent countries which are yet to begin
vaccinating against HPV. In such a way, we showed
how impacts changed depending on both the cover-
age of vaccination in the population and existing herd
immunity.
Economic model
The economic model took the form of a continuous time
individual patient simulation (Additional file 2: Appendix
S2), using output from the epidemiological model (specifi-
cally, times of infection and recovery, with each HPV type,
for each individual in the model). The economic model
then extrapolated these data to clinical events experienced
by each individual over their lifetime (up to a maximum
age of 100 years old). The healthcare costs and quality-
adjusted life years (QALYs) for each vaccination strategy
were compared to a baseline strategy (either no vaccina-
tion or girls only) and the incremental cost-effectiveness
ratio of each strategy was estimated. We then generated
the threshold vaccine dose price; that is, the maximum
amount the healthcare system is willing to pay given the
associated health benefits (currently set at £20,000 per
QALY in the UK). Positive prices per vaccine dose below
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this threshold price will tend to generate positive net
health benefits, whilst negative prices per vaccine dose
offer no incentive to the manufacturer to provide the
vaccine.
The economic evaluation was conducted from a UK
National Health Service (NHS) and personal social ser-
vices perspective with costs presented in pounds sterling
(2013-14 prices). The following sections outline the basic
clinical, cost and health utility parameters that fed into
this economic model.
Clinical parameters
Age- and sex-specific incidences of the six cancer types
included in the model (cervical, anal, vaginal, vulvar,
penile, oropharyngeal), and cervical intraepithelial neo-
plasia were taken from 2013 UK cancer registration statis-
tics. Age- and sex-specific incidences of genital warts
were taken from a UK Health Protection Agency report
[55], and age specific incidences of recurrent respiratory
papillomatosis from a task force on recurrent respiratory
papillomas [56].
Proportions of each of these clinical events associated
with the HPV types included in the model were extracted
from a published meta-analysis [57] and a literature
review undertaken by Jit and colleagues [22] (Additional
file 6: Table S4). It was often not possible to distinguish
between events caused by types 6 and 11, so these were
modelled as a single risk factor in the economic analysis.
The same was true for events caused by types 31, 33, 45,
52 and 58.
Data on disease incidence, proportion of disease associ-
ated with HPV, and age- and sex-stratified proportions of
people infected with each HPV type pre-vaccination were
combined to give annual event rates for the nine diseases
included in the model, stratified by age, sex and current
and past HPV infection status.
All-cause mortality data were taken from the Office of
National Statistics [58], as were age-specific one and five
year survival data for cervical cancer [59, 60]. Data for
other cancers were not available from the same source.
Anal cancer survival rates were taken from an epidemi-
ological study conducted by Jeffreys and colleagues [61],
and those for other cancers from an Office for National
Statistics report on survival rates from less common can-
cers [62]. However, since these data were old, the sur-
vival rates were adjusted to estimate contemporaneous
values, using improvements in cervical cancer survival
over the same time period. Mortality rates from recur-
rent respiratory papillomatosis were taken from a study
by Bishai and colleagues [63]. For oropharyngeal cancer
we use the proportion attributable to HPV from [64], and
allow this proportion to increase up to 80% when sam-
pling from economic parameters, to account for recent
data [65].
Health utilities
Health utility decrements associated with cases of genital
warts [66] and recurrent respiratory papillomatosis [63]
were extracted from the literature. Health utility decre-
ments associated with cancer consisted of two compo-
nents, a short time loss during treatment, and a long term
health utility decrement which persisted for the remainder
of the individual’s life.
Costs
Costs of recurrent respiratory papillomatosis [67], gen-
ital warts [68], and cervical cancer [69] were all taken
from the literature and inflated to 2013-14 UK prices.
Costs for other cancer types were not available for the
UK. Therefore, the relative costs (compared to cervical
cancer) for these cancers were estimated from the HPV-
ADVISE model [22], and these were indexed against the
cost of cervical cancer in the model to obtain estimates
of cost for other cancer types. The cost of vaccination
administration was assumed in the baseline analysis to be
£10 per dose (Department of Health, personal commu-
nication), and we assumed a two dose schedule (vaccine
plus booster) following evidence that this is likely to be
more cost-effective than three doses if vaccine protection
is at least 20 years [29]. Given the high level of completion
in the UK, we assumed for simplicity that all immunised
individuals were given both doses, hence calculating the
costs and impact of vaccination was straightforward. If a
significant fraction of the population only received one
dose, this might skew both the health impacts and the
associated costs; however, this is not the case in the UK -
in 2017/18, 83.9% received two doses while just 5.2% only
received one dose and 10.7% did not receive any vaccine.
The costs and health utility decrements used in the
model are summarised in Additional file 7: Table S5.
Time horizon and discounting
The time horizon of the base case model was 100 years
post the point where the different vaccine strategies
affected individuals in the model. Thus, people who were
born at the start of 2000 were included in the analysis, as
were all subsequent newborns.
To comply with the JCVI’s guidelines, two criteria were
considered. Firstly, that for the most likely set of param-
eters (modes of posteriors) the mean discounted costs
and outcomes should be evaluated against a £20,000 cost-
effectiveness threshold value for a QALY [70]. Secondly,
to account for uncertainty, 90% of all posterior parame-
ters should generate cost-effective results at a threshold of
£30,000 per QALY. In both cases discounting at a rate of
3.5% per year (for both healthcare costs and QALYs) was
used.
As an alternative scenario, we also evaluated the effects
of applying a 1.5% discount rate to health impacts; this was
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in response to the CEMIPP report [71] which highlighted
that 3.5% discounting was not always appropriate given
disparate delays from infection time to health effects, and
alternative discounting rates should be considered where
appropriate. This is the case for HPV, when there may be
many years between vaccination, infection and the onset
of life-threatening cancers. 1.5% was chosen in response
to the appraisal by the National Institute of Care Excel-
lence, which noted that “A discount rate of 1.5% for costs
and benefits may be considered by the Appraisal Commit-
tee if it is highly likely that, on the basis of the evidence
presented, the long-term health benefits are likely to be
achieved” [70].
For the uncertainty criterion, we note that a single simu-
lation contains stochasticity due to both parameter uncer-
tainty, and also the finite size of the modelled population
and the chance nature of transmission. Our results show
that this second form of stochasticity is largely parameter
invariant, and therefore we were able to separate these two
effects (Supplementary Material). The results shown for
the uncertainty analysis therefore reflect only our uncer-
tainty in parameter estimates and not variability between
simulations.
Patient Involvement
Patient and public involvement (PPI) in research has
become embedded in health research with patients and
the public involved as collaborative partners through
the research process [72, 73]. While common in health
research, public involvement in mathematical and eco-
nomic modelling is relatively rare, with few examples of
embedded forms of collaborative involvement and a lack
of agreed methodology for PPI in modelling.
For this analysis, patients and the public were not
involved in developing either the research question or the
design of the study in relation to the modelling approach,
primarily because this is one of the first studies to include
PPI in modelling. As such it is exploratory in nature, with
our intention to identify the ways in which patients can
contribute to modelling. We utilised the development of
the HPVmodel as an opportunity to establish a PPI Refer-
ence Group (comprised of publicmembers), to explore the
potential for patients or the public to contribute to both
the epidemiological and economic modelling components
of the study, as part of the wider programme of work.
The Reference Group met regularly at key points in the
study, with email contact in between. The wider aim of
PPI within the project was to contribute towards concep-
tual development of PPI in mathematical and economic
modelling, through the development of a new framework
co-produced with patients and the public. Throughout the
project we aimed to identify any impacts of the PPI Refer-
ence Group, and these will be disseminated through policy
recommendations made by the Department of Health. A
separate piece of work on the PPI contribution to the study
is currently in progress.
Results
The fitting scheme produced well-defined parameter dis-
tributions (see Additional file 8: Figure S1 and Table
S6), and simulating using the distributions provided good
agreement between the model and data (see Additional
file 9: Figures S2 and S3). In the following sections the
effects of varying vaccination strategy on HPV prevalence,
incremental cost-effectiveness and the consequences for
threshold vaccine dose prices, are presented.
Epidemiological effects of vaccination strategies
The predicted effect that a range of vaccination strategies
would have on the prevalence of HPV is shown in Fig. 1.
The eight years of girls-only vaccination (2008-2016)
had the effect of reducing HPV prevalence across the
entire population (both male and female) from approxi-
mately 8% to 6.9%. Assuming that girls-only vaccination
continues at 85%, by 2050 prevalence is predicted to drop
to around 0.56% (yellow line). Adding boys’ uptake at
85% to the girls-only programme from 2017 onwards fur-
ther reduces prevalence to approximately 0.13% (green
line). As an alternative, keeping the number of vaccina-
tions equal to the girls-only programme but splitting them
equally between girls and boys (so that uptake is 42.5%
in both sexes) leads to a less steep decline in prevalence,
falling to around 1.5% by 2047 (blue line). Interestingly,
halting vaccination entirely in 2017 leads to a contin-
ued fall in prevalence until 2025 (red line), due to the
delay between vaccination and girls entering the sexually
active population; however, in the longer term prevalence
returns to approximately pre-vaccination levels.
As an alternative to the eight years of girls-only vac-
cination at high uptake, we investigated the effect of a
lower uptake HPV vaccination campaign from 2008. Vac-
cinating just 60% of girls leads to a less marked decline in
prevalence, reducing to around 2.5% by 2050 (black solid
line); vaccinating 60% of both sexes further reduces the
prevalence to 0.31% (black dashed line).
We note that, due to basing pre-2010 individual-
level behaviour on Natsal-2 and post-2010 behaviour
on Natsal-3 which reported marginally increased sexual
behaviour [74], we observe slight increases in baseline
prevalences from 2010 onwards. This can be seen most
easily by contrasting prevalence pre-vaccination with val-
ues at 2050 for halted vaccination (7.97% and 8.02%
respectively).
These results have two important public-health impli-
cations. Firstly the reduction in cases from adding boys to
the vaccination program is markedly less that the initial
impact of adding girls. Secondly, a gender-neutral cam-
paign vaccinating 60% of the population has comparable
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Fig. 1 The effects of different vaccination strategies on the prevalence of HPV in the population, over the 30 years following a change in strategy.
Strategies tested include: halted vaccination (red), girls only at 85% (yellow), girls/boys at 85%/85% (green), girls/boys at 42.5%/42.5% (blue), girls at
60% from 2008 (black solid), and girls/boys at 60%/60% from 2008 (black dashed). All strategies use the nonavalent vaccine
impact on infection prevalence as vaccinating 85% of girls
(42.5% of the population). Given the heterosexual nature
of the majority of the UK population, it is clear that vac-
cination of girls is generating considerable herd-immunity
for boys.
A detailed breakdown in the prevalence of different
HPV strains, by age and gender, under alternative vacci-
nation strategies is given in Additional file 11: Table S7.
As might be expected, strains decrease according to the
level of protection afforded by the vaccine as in Addi-
tional file 5: Table S3; for example, as strains 6 and 11 are
not covered by the bivalent vaccine, prevalences of these
strains are comparable between the strategies of halted,
girls-only bivalent and gender-neutral bivalent vaccina-
tion. If the strain is covered by the vaccine, girls-only
vaccination reduces strain prevalence significantly com-
pared to halted vaccination, while adding boys to the
girls-only programme has a more limited effect (e.g. for
26-35 year old males, strains 31/33/45/52/58 and the non-
avalent vaccine, girls-only vaccination reduces prevalence
from 10.2% to 2.05%; gender-neutral vaccination reduces
prevalence to 0.658%, a lower incremental benefit).
Cost-effectiveness of vaccination strategies
The mean results of the cost-effectiveness model are
shown in Fig. 2 and Table 1, with the distribution of
threshold prices shown in Additional file 10: Figure
S4. Threshold dose prices for cost-effectiveness, using
both 3.5% and 1.5% discounting, with a £20,000 cost-
effectiveness threshold value, are shown for all vaccina-
tion strategies versus halted vaccination, and for gender-
neutral strategies versus girls only. Prices are shown for
the cost per dose, assuming a two-dose schedule, and a
£10 administration charge for each dose.
Vaccinating girls only or both girls and boys, with any
of the vaccines, was always cost-effective compared to
not vaccinating, with positive threshold dose prices and
positive confidence intervals in all instances. However,
vaccinating girls alone was more cost-effective per dose,
with a higher threshold price for each vaccine, compared
to a gender-neutral strategy. Generally, the nonavalent
vaccine was the most effective in preventing disease, fol-
lowed by the quadrivalent, and finally the bivalent, as
would be expected from the level of protection offered,
hence a greater threshold price. Incremental to a girls-only
vaccination campaign, adding boys gave threshold dose
prices very close to, but below, zero, at 3.5%. The results
from individual simulations varied widely and 500 repli-
cates were needed to achieve relatively tight confidence
intervals around the mean. For the quadrivalent vaccine,
the mean dose price was negative (at -£2.92) and, given
that the confidence intervals are below zero (from -£3.64
to -£2.18), we can say with 95% confidence that the thresh-
old price is negative. The same arguments apply to both
the bivalent and nonavalent vaccines.
At 1.5% discounting all threshold prices increased, but
with the same qualitative patterns; for girls-only vaccina-
tion compared to halted vaccination threshold prices were
£687 – £811 for the three vaccines and gender-neutral vac-
cination was less cost-effective, with threshold prices of
£362 – £429. Incremental to girls only, gender-neutral vac-
cination had positive threshold prices of £36 – £47. This is
due to the lower discount rate adding more weight to eco-
nomic values placed on health conditions in the future. In
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Fig. 2 Threshold dose prices for various vaccination strategies, considering a two-dose schedule. All plots assume £20,000 cost-effectiveness
threshold for a QALY, modal parameters from posterior used, and a £10 administration charge per dose. Mean values are shown as crosses, with
95% confidence intervals shown by bars. Colours correspond to the three vaccines: bivalent (red), quadrivalent (blue) and nonavalent (green). Top
plots assume 3.5% discount rates applied, bottom plots assume 1.5% discount rates applied. Left plot: comparing girls-only and gender-neutral
vaccination to halted vaccination. Right plot: comparing vaccination of gender-neutral vaccination to continuing girls-only vaccination. When
comparing a strategy to girls-only vaccination the same vaccine is used for correct comparison
general, a lower discounting rate will always make vacci-
nation more cost-effective for infections like HPV, where
the health consequences are experienced years or decades
after infection.
A detailed breakdown in the reduction in cases of the
health sequelae under alternative vaccination strategies is
given in Additional file 12: Table S8. Asmight be expected,
there is a large decrease in cases of health sequelae when
vaccinating girls compared to halted vaccination, while
adding boys to the girls-only programme yields a much
smaller decrease in cases. Incremental cost-effectiveness
ratios (ICERs) for alternative vaccination strategies are
shown in Additional file 13: Tables S9 and S10, and Figure
S5, at a range of assumed vaccine dose prices. Relative
Table 1 Threshold dose prices for various vaccination strategies, considering a two-dose schedule
Vaccination strategy £, versus halted vac. (3.5%) £, versus girls’ vac. (3.5%) £, versus halted vac. (1.5%) £, versus girls’ vac. (1.5%)
Girls, bivalent 55.80 (55.04 – 56.57) - 687.47 (675.62 – 699.20) -
Girls, quadrivalent 99.64 (98.90 – 100.37) - 752.46 (740.51 – 764.72) -
Girls, nonavalent 108.05 (107.36 – 108.75) - 811.44 (801.18 – 821.68) -
Girls & boys, bivalent 25.08 (24.64 – 25.52) -5.67 (-6.42 – -4.93) 361.99 (356.09 – 367.85) 36.46 (26.82 – 45.98)
Girls & boys, quadrivalent 48.38 (47.95 – 48.80) -2.92 (-3.64 – -2.18) 398.68 (392.65 – 404.84) 44.70 (35.42 – 53.81)
Girls & boys, nonavalent 52.77 (52.42 – 53.10) -2.56 (-3.13 – -1.99) 429.26 (422.98 – 435.44) 46.88 (37.63 – 56.46)
Mean values shown over 500 simulations, with 95% confidence intervals in brackets. All strategies assume a £20,000 cost-effectiveness threshold for a QALY, with both 3.5%
and 1.5% discount rates applied, and a £10 administration charge per dose. When comparing a strategy to girls-only vaccination the same vaccine is used for correct
comparison
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to halted vaccination, girls-only vaccination results in
lower ICERs than a gender-neutral programme (Addi-
tional file 13: Tables S9), while ICERs are significantly
higher for a gender-neutral programme compared with
girls-only vaccination, signalling low cost-effectiveness
(Additional file 13: Tables S10).
Employing the probabilistic approach as per the JCVI’s
guidelines, whereby parameters in both the transmission
and economicmodels were sampled from appropriate dis-
tributions, and increasing the cost-effectiveness threshold
for a QALY to £30,000, the threshold dose prices at the
10th percentile of simulated values (for bivalent, quadri-
valent and nonavalent vaccines, and at both 3.5% and 1.5%
discount rates) are shown in Table 2, and the cumula-
tive distribution of threshold dose prices are displayed in
Fig. 3.
It is evident that, while vaccination of girls fulfilled
the JCVI criterion of 90% of simulations generating cost-
effective results (Fig. 3a), adding boys to an existing girls-
only campaign at 3.5% discounting did not satisfy the
condition (Fig. 3b). For all three vaccines, the 10% bound-
ary in the cumulative distribution for threshold dose price
lay below zero - meaning that, by the JCVI guidelines for
uncertainty, adding boys is not cost-effective - further sup-
porting the conclusion from the results using the most
likely parameters.
Conversely, at 1.5% discounting (Fig. 3c) all three vac-
cines had positive values at the 10% boundary (£45 – £67).
Hence at 1.5% both criteria for cost-effectiveness are met.
We note that the 10% boundary price for the quadriva-
lent vaccine is higher than for the nonavalent (at both 3.5%
and 1.5% discounting). We suggest this is because vacci-
nating girls only with the nonavalent vaccine induces herd
immunity against all 9 HPV types such that the addition
of vaccinating boys has limited impact; in contrast, given
that the quadrivalent vaccine induces only limited herd
immunity against types 31, 33, 45, 52 and 58, including
vaccination of boys has amore substantial impact on these
types.
Considering the different levels of vaccine uptake in
more detail and the resulting herd-immunity provides
a richer understanding of the cost-benefit relationship
(Fig. 4). Two elements contributed to the low threshold
dose price previously described. The first is that, as the
uptake rate of vaccination in both boys and girls increased,
so the threshold dose price decreased; this is because of
the herd immunity generated by immunising an increased
proportion of girls such that much of the vaccination in
boys was effectively “wasted”, i.e. the majority of men who
were vaccinated as adolescents will not be subsequently
exposed to infection. The second is that the high vaccina-
tion uptake rates observed so far in the UK, have already
generated such high levels of population protection that
the impact of vaccinating boys was further reduced (Fig. 4,
circle markers compared to square markers). Thus, if
uptake is expected to be low across a population, then
introducing a gender-neutral scheme early is expected to
be highly beneficial; for example, at 3.5% discounting and
assuming uptake was just 10%, the mean threshold price
for adding boys was £112.37 (111.35 - 113.40) without
prior vaccination or £78.11 (76.60 - 79.58) if girls had been
vaccinated for eight years as assumed elsewhere in this
paper.
We note that, using 3.5% discounting (Fig. 4a), at 85%
uptake (dashed vertical line) the cost-effectiveness of
gender-neutral vaccination drops below zero for a popu-
lation with UK vaccination up until present, whereas it is
positive for a vaccination-naïve population. As with the
previous simulations, decreasing the discounting rate to
1.5% increases all threshold prices (Fig. 4b), with positive
prices up to and including 90% uptake rates.
Discussion
The modelling work performed here combined epidemi-
ological and economic insights with advice from our PPI
group, and provides cost-effectiveness results for a vari-
ety of vaccination strategies to combat HPV, following
standard methodologies (e.g. [19, 26, 75–77]. Previous
studies have predicted that vaccination of girls would
be highly cost-effective [19, 26, 75], with concomitant
decreases in levels of HPV infection (and associated
adverse health sequelae) [9, 10, 78–80]. The majority of
Table 2 The threshold dose prices at the 10th percentile of simulated epidemiological and economic values (over 500 simulations),
using both 3.5% and 1.5% discount rates and an increased cost-effectiveness threshold of £30,000, compared to both halted
vaccination and girls-only vaccination, with a £10 administration charge per dose
Vaccination strategy £, versus halted vac. (3.5%) £, versus girls’ vac. (3.5%) £, versus halted vac. (1.5%) £, versus girls’ vac. (1.5%)
Girls, bivalent 68.07 - 1024.71 -
Girls, quadrivalent 140.85 - 1121.74 -
Girls, nonavalent 147.90 - 1232.70 -
Girls and boys, bivalent 32.13 –6.38 577.45 45.06
Girls and boys, quadrivalent 74.95 -4.84 654.07 67.12
Girls and boys, nonavalent 81.12 -6.04 676.54 49.89
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Fig. 3 Threshold dose prices for girls-only vaccination compared to halted vaccination (at 3.5% discounting, left plot), and gender-neutral
vaccination compared to girls-only vaccination (at 3.5% discounting, middle plot, and at 1.5% discounting, right plot). Coloured lines show different
vaccines: bivalent (red), quadrivalent (blue) and nonavalent (green). Threshold dose prices at the 10th percentile of simulated values highlighted by
coloured lines from x-axis to curve. Vertical black dashed line indicates £0 threshold price. Results shown for 500 simulations
previous economic analyses indicated that adding boys to
the girls-only programme is unlikely to be cost-effective
(e.g. [24, 26, 43, 45, 81]. The results presented here echo
these findings, but provide both a UK-specific context and
a broader scientific understanding of the impact of vaccine
uptake and economic discounting.
Our fitted epidemiological model provides a good
match to the available datasets. The use of likelihood-
based techniques and Bayesian MCMC methodology
meant that we could account both for inconsistencies
between data sets and uncertainty in parameter estimates.
In particular, while parameter estimates for the main HPV
types (6, 11, 16 and 18) are well defined, there is greater
uncertainty surrounding the additional five types in the
nonavalent vaccine (31, 33, 45, 52 and 58), reflecting the
sparsity of data sources (Additional file 9: Figures S2 and
S3). A lower probability of serological response in men
compared to women is in agreement with a recent meta-
analysis on natural immunity [82]; although that study
found immune period difficult to determine due to a lack
of knowledge of infection time, our model suggests a
period of around 1.4 years.
Vaccination of girls has been observed to lower the pop-
ulation prevalence of HPV [11, 80], and our models sug-
gest that in the UK this trend is likely to continue (Fig. 1,
yellow line). Even if vaccination is stopped, the time-delay
between vaccinating young girls and them entering the
sexually active population means that prevalence will con-
tinue to fall for another nine years before finally returning
to pre-vaccination levels of around 9.5% (for any of the
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Fig. 4 The mean threshold vaccine dose price for gender-neutral vaccination compared to girls-only vaccination, using the quadrivalent vaccine, for
a 3.5% discounting and b 1.5% discounting. Two initial conditions are tested: assuming no vaccination has previously occurred (square markers), or
assuming uptake in girls as in the UK historically for 2008-2016 (circle markers). 95% confidence intervals shown for all points. Vertical dashed line
highlights 85% uptake, which is the rate assumed for girls-only and gender-neutral vaccination in the future in this paper. 200 simulations carried
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nine types modelled here). A girls-only vaccination cam-
paign with 85% uptake with the nonavalent vaccine is
expected to reduce population prevalence to around 1%
within forty years. This value is further reduced to just
0.2% if boys are also included in the vaccination scheme.
Therefore, we find that while introducing vaccination in
young girls leads to a reduction in prevalence of around
90%, adding boys to this scheme only provides a limited
further reduction in prevalence. Given that the majority of
HPV transmission is through heterosexual relationships
(so the infection must pass through a male-female-male-
female . . . chain), it is clear that completely protecting
either sex is sufficient to halt heterosexual transmission.
This helps to explain why adding boys to an effective
girls-only programme has limited effect. The exception
to this is MSM, where there is limited herd-immunity
from the girls-only programme, and so vaccination could
be expected to be highly effective [34, 35, 47]. However,
a mass (i.e. untargeted) vaccination programme of boys
does not target this group.
In general, any additional vaccination will always reduce
the prevalence of infection and hence the expected
amount of disease; furthermore, greater reductions are
naturally predicted for vaccines that provide protection
against more HPV types. To understand whether these
declines are worth the additional costs of vaccination,
requires us to undertake a health economic evaluation
comparing health benefits against vaccine-related costs
and associated costs. All tested strategies were cost-
effective (at the £20,000 cost-effectiveness threshold for a
QALY and assuming 3.5% annual discounting) compared
to halted vaccination. Girls-only vaccination was highly
cost-effective versus halted vaccination, with threshold
dose prices of £55.80, £99.64 and £108.05 for the biva-
lent, quadrivalent and nonavalent vaccines, respectively
(Table 1). Gender-neutral vaccination was also cost-
effective versus halted vaccination, although at lower
threshold dose prices of £25.08, £48.38 and £52.77 for
the three respective vaccines. All threshold prices were
higher at 1.5% discounting, but the same qualitative pat-
tern observed (Table 1).
Comparing gender-neutral vaccination with girls-only
vaccination (that is the cost-effectiveness of adding boys),
none of the vaccines had a positive dose threshold price at
3.5% discounting (-£5.67, -£2.92 and -£2.56 for the three
vaccines), with confidence intervals that were all below
zero (Table 1). Moreover, following UK guidelines for
economic evaluations of immunisation programmes, we
examined the uncertainty in our predictions. Even remov-
ing between-simulation stochasticity, the uncertainty in
parameter estimates was such that there is a less than 10%
chance that gender-neutral vaccination is cost-effective
(compared to girls-only) at a cost-effectiveness threshold
value for a QALY as high as £30,000 (Fig. 3b). In contrast,
when comparing all strategies to halted vaccination, the
recommended probabilistic threshold is always achieved
(Table 2).
At 1.5% discounting all threshold dose prices increase,
and gender-neutral vaccination, incremental on girls-
only vaccination is cost-effective, with threshold prices of
£36.46, £44.70 and £46.88 (Table 1). There is also a greater
than 90% chance that gender-neutral vaccination is cost-
effective (compared to girls-only) at a cost-effectiveness
threshold value of £30,000 per QALY (Fig. 3c). Recent
recommendations from the CEMIPP report [71] and the
JCVI [83] suggest applying a lower discount rate to the
health effects of HPV vaccination, given the long time
delay between infection and the onset of adverse sequelae.
There is some empirical evidence of cross-protective
effects of the bivalent vaccine against warts-causing types
6 and 11 [10, 84]. Although we have not tested the
assumption here, the fact that the quadrivalent and non-
avalent vaccines (which offer complete protection against
6 and 11) are not cost-effective for a gender-neutral pro-
gramme at 3.5% discounting, means that adding these
cross-protective effects will not change the conclusions
reached.
As vaccine coverage in girls increases, so herd-
immunity builds up, making additional vaccination less
worthwhile. Hence, with higher uptake rates in girls (and
longer historical vaccination of girls), boys’ vaccination
becomes less cost-effective (Fig. 4). This is a critical result,
as it shows that in the UK, where uptake in girls has
historically been so high [11, 54] adding boys is not a
cost-effective option. Conversely, in other countries where
existing girls-only programmes have lower uptake rates
(such as the USA and France [13]) adding boysmay indeed
still be cost-effective. This is due to the higher preva-
lence of infection remaining in the population, leading
to potentially more significant declines in the incidence
of adverse health effects such as cervical and oropharyn-
geal cancer. Similarly, including boys in the vaccination
scheme can buffer the programme against fluctuations
in level of vaccine uptake [85]. This impact of uptake in
girls, echoes previous findings. Given the significant vari-
ation in uptake of the girls’ programme between countries
[12], we would expect to observe a threshold below which
gender-neutral vaccination was economically acceptable;
however, the reality is more ambiguous. In particular, Aus-
tralia, New Zealand and Canada have recently added boys
to their respective national vaccination programmes, and
uptake rates are 71% [13], 40-56% [13, 15] and 39-89%
[86, 87] in these respective countries. For New Zealand
this contradicts a recent study which found that adding
boys would not be cost effective [43]. Clearly, these health
economic arguments are strongly influenced by the vaccine
price,with recent reductions in average tender prices favour-
ing the adoption of a gender-neutral programme [88].
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Girls carry a larger economic burden of HPV-related
disease than boys [89], due to the relatively high incidence
of cervical cancer, so they are always the primary target for
vaccination. This is evidenced in Additional file 12: Table
S8, where the incidence of cervical cancer with halted
vaccination is higher than all cancers except for oropha-
ryngeal cancer. The addition of boys’ vaccination gives
small reductions in prevalence of these health effects,
in comparison to vaccinating girls alone. Combining the
incidence rates in Additional file 12: Table S8 with the
costs and QALY decrements in Additional file 7: Table S5,
we calculate the main cost-saving impact of adding boys
is reductions in oropharyngeal cancer and genital warts,
with cervical cancer reduction having reduced savings. In
low uptake countries, questions remain as to whether it
would be more cost-effective to vaccinate boys or to try to
increase the coverage in girls, with more studies suggest-
ing the latter [39]. Recent work, however, has highlighted
the increasing importance of other cancers as HPV vac-
cination programmes lead to declines in cervical cancer
cases [90].
It is clear from our analysis that mixing patterns are
an important factor in the spread of HPV. An aspect
not explicitly modelled here was the possibility of disease
import from outside the population (i.e. immigration and
tourism). This has been considered in some of our work,
but unprotected sex with unvaccinated individuals from
outside the UK is likely to be a relatively minor component
[91]. It is also likely to be highly non-random in a way in
which there is little data to support any assumption.
One limitation of our modelling approach is the decou-
pling of HPV vaccination from cervical cancer screening –
we have implicitly assumed throughout this work that cer-
vical cancer screening will continue in its current form. It
is possible that the nature of (and hence costs and conse-
quences of ) the cervical cancer screening programme will
change in the future. In the near term this is most likely
to be caused by evidence showing HPV-based cervical
screening is more effective than the current cytology-
based programme, and supports increasing the screening
intervals from three to five years [92]. A programmatic
change to primary HPV testing for cervical cancer is pre-
dicted to reduce cervical cancer incidence [93]; this has
the potential to reduce the estimated cost-effectiveness of
HPV vaccination in the UK. On the other hand, screen-
ing programmes could change directly as a result of the
HPV vaccination programme; it has been estimated that
the successful use of the bivalent vaccine could reduce
the need for more than three cervical smears per life-
time [94]. A recent study from Australia concluded that,
if continued gender-neutral vaccination was maintained
into the future, cases of cervical cancer could reduce
from seven cases per 100,000 women to less than four by
2028 [95]. Overall, while the current cervical screening
programme is implicitly accounted for in our study (ignor-
ing any possible fluctuations in screening participation by
year/age/vaccination status), we do not account for the
impact of future changes to screening technology, inter-
val and compliance. Thus, far more research is needed to
inform best policy on the interaction between HPV vac-
cination and cervical cancer screening. Future changes to
the cervical cancer screening programme are beyond the
remit of this study, but are an important area of focus for
future research.
A key assumption in our models, whichmay require fur-
ther study is that vaccination is an independent random
process, and in particular is not correlated with sexual
behaviour. If this is not appropriate, it may be that the girls
who are missing out on vaccination are in the highest risk
groups, and may be disproportionately contributing to
transmission of HPV. Due to the high prevalence of HPV
across both men and women [96–98], this seems unlikely
to have a significant effect on the dynamics of infection,
although other modelling studies have shown that the cor-
relation does not need to be big to have an impact [99].
Whilst there is no clear consensus of drivers of vaccine
uptake at a community-level [12], there is more evidence
at the individual level of a relationship between vaccina-
tion and risk behaviour [100, 101]. When risk is highly
clustered to particular groups, for example for hepatitis-B,
then the ability to target these groups becomes critical to
the decision to vaccinate [102]. An important follow-up to
this work would be to assess the importance of low- and
high-risk infection groups, their likelihood of vaccination,
the mixing between the two groups, and the effectiveness
of vaccination given the relative coverage in the high-risk
group.
Conclusions
The generic conclusion from this work is that as cov-
erage in girls increases, there is less incremental benefit
from adding boys to the programme, due to existing herd-
immunity. In the case of the UK, with the highest reported
sustainedHPV vaccine uptake rates in girls of any country,
it is unlikely that adding boys will be cost-effective within
standard economic guidelines which assume a 3.5% eco-
nomic discounting. However, given the long time-scales
associated with HPV infection and resulting disease, it
may be more appropriate to adopt a 1.5% discounting,
in which case adding boys to the programme becomes
cost-effective for all three vaccines considered.
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